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Abstract: The use of inotropes for correcting hemodynamic dysfunc-
tion in patients with congestive heart failure has been described over
many decades. However, negative or insufﬁcient data have been collected
regarding the effects of cardiac glycosides, catecholamines, and phos-
phodiesterase inhibitors on quality of life and survival. More recently, the
calcium sensitizer and potassium channel-opener levosimendan has been
proposed as a safer inodilator than traditional agents in some heart failure
settings, such as advanced heart failure. At the 2017 annual congress of
the Heart Failure Association of the European Society of Cardiology
(Paris, April 30–May 2), a series of tutorials delivered by lecturers from 8
European countries examined how to use levosimendan safely and effec-
tively in acute and advanced heart failure. The proceedings of those
tutorials have been collated in this review to provide an expert perspective
on the optimized use of levosimendan in those settings.
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INTRODUCTION
Levosimendan is a ﬁrst-in-class drug that acts as an
inodilator through a tripartite mechanism which involves acting
as a calcium sensitizer in cardiomyocytes by increasing the
sensitivity of troponin C ﬁbers to ionic calcium and as
a vasodilator and cytoprotective agent through the opening of
adenosine triphosphate (ATP)-dependent potassium channels on
vascular smooth muscle cells and in mitochondria.1 Since its
introduction at the beginning of the 21st century, levosimendan
has been evaluated extensively for the treatment of acute heart
failure (AHF) and in a range of other settings characterized by
impaired cardiac performance, including cardiac surgery and
sepsis.2 Among drugs broadly classiﬁed as inotropes, levosimen-
dan is the most widely researched agent of the past 20 years.3
The hemodynamic effects of levosimendan in heart
failure comprise signiﬁcant, dose-dependent increases in
cardiac output (CO) and stroke volume and reductions in
pulmonary capillary wedge pressure (PCWP) and pulmonary
artery pressure.4 These effects are seen early after the initia-
tion of intravenous (i.v.) levosimendan therapy and persist
(for up to z10 days) after cessation of infusion through the
inﬂuence of the long-acting active metabolite OR-1896.1
Multiple meta-analyses have identiﬁed tangible clinical
beneﬁts from levosimendan; in particular, it is reported to be
the only inotrope associated with improved survival2,3 and
has also been linked with reduced risk of deterioration of
heart failure and the associated likelihood of hospitalization.5
Recent interest has been directed toward the use of
repeated cycles of i.v. levosimendan to avert acute decompen-
sation and frequent rehospitalization in patients with advanced
heart failure (AdvHF) and possibly to enhance health-related
quality of life.6 Unlike dobutamine, levosimendan is effective in
patients who have been treated with beta-blockers, and unlike
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milrinone, it is not detrimental to patients with AHF of ischemic
origin.7,8 These qualities add to the distinctiveness of levosimen-
dan among inotropic agents and are reﬂected in its inclusion in
the most recent editions of the European Society of Cardiology
(ESC) guidelines for the treatment of heart failure as part of the
armamentarium of drugs for the treatment of AHF.9
This focused review examines 3 current themes in the
use of levosimendan: management of AdvHF, treatment of
AHF, and preservation of renal function in heart failure.
INODILATORS IN AHF
Guidelines of the European Society of
Cardiology
The 2016 ESC guidelines for the management of AHF
endorse the use of inotropes for “patients with hypotension [sys-
tolic blood pressure (SBP) ,90 mm Hg] and/or signs/symptoms
of hypoperfusion despite adequate ﬁlling status to increase cardiac
output, increase blood pressure, improve peripheral perfusion, and
maintain end-organ function.” Inotropes are also endorsed “.to
reverse the effect of beta-blockade if (that) is thought to be con-
tributing to hypotension and subsequent hypoperfusion.”9
Pharmacology considerations and clinical data support
the view that levosimendan may be well suited to the needs of
patients in those situations.
Calcium Sensitization Versus Calcium
Mobilization
Levosimendan is differentiated profoundly from tradi-
tional inotropes by the fact that it is a calcium sensitizer that
enhances the response of cardiomyocytes to a given concen-
tration of intracellular ionic calcium.1 By contrast, adrenergic
stimulants, digoxin, and phosphodiesterase inhibitors are all
calcium mobilizers that increase the concentration of ionic-
free calcium in cardiomyocytes. Calcium mobilizers therefore
expose cardiomyocytes to potentially toxic concentrations of
ionic calcium and, inter alia, increase myocardial oxygen
consumption; levosimendan has neither effect.
In addition, levosimendan exerts vasodilator and car-
dioprotective effects through action on potassium-dependent
ATP channels on cardiac mitochondria and vascular smooth
muscle cells1 (Box 1). These are signiﬁcant ancillary actions
in the context of AHF with hypoperfusion, venous congestion
and endothelial impairment, and deteriorating end-organ
(notably renal) function and likely contribute to the quality
of symptom relief achievable with levosimendan.
BOX 1.
Levosimendan acts as an inodilator through
a tripartite mechanism
1. Increasing the sensitivity of cardiomyocyte troponin C
ﬁbers to ionic calcium;
2. Opening of adenosine ATP-dependent potassium chan-
nels on vascular smooth muscle cells;
3. Opening of adenosine ATP-dependent potassium chan-
nels in mitochondria.
In aggregate, these pharmacological differences have
a wide-ranging impact on the risk–beneﬁt proﬁle for both
types of agent and strongly favor levosimendan. Although
calcium mobilizers are associated with tachycardia and ar-
rhythmias, proischemic effects, cardiac hypertrophy, apopto-
sis and ﬁbrosis, and worse medium- to long-term prognosis,
levosimendan enhances CO and systolic and diastolic func-
tion, promotes vasodilatation and peripheral perfusion, re-
duces (PCWP), alleviates symptoms of dyspnea and fatigue,
and reduces levels of signiﬁer neurohormones such as brain
natriuretic peptide (BNP).10
Perhaps the most signiﬁcant of all, given the safety
concerns attached to inotropes in the 2016 ESC guidelines, is
the fact that the mixed inodilator proﬁle of levosimendan is
associated in routine clinical practice with a mortality rate
lower than that seen with calcium-mobilizing inotropes and
much closer to that achieved with vasodilators (Fig. 1).11
Vasodilation, Venous Congestion, and
Hypoperfusion
The vasodilator aspects of the clinical pharmacology
of levosimendan are likely to be very relevant to the drug’s
application in low-output states such as AHF and cardio-
genic shock. The description of these conditions as “low-
output states” is accurate but potentially misleading, given
that the central concern in many cases is organ underperfu-
sion. Accordingly, the use of a drug that evokes vasodilata-
tion and augmenting CO may be expected to have a more
favorable impact on the prognosis of patients than one that
acts only as a cardiac stimulant or which has pressor effects.
It may be debated that, in general, a ﬁxation on raising SBP
in response to organ hypoperfusion is inappropriate and that
at least some patients are being overtreated to maintain
FIGURE 1. In the ALARM-HF registry, the mixed inodilator
profile of levosimendan was associated with a mortality rate
substantially lower than that seen with traditional (“calcium-
mobilizing”) inotropes, from data by Mebazaa et al.11
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blood pressure at the expense of restoring appropriate organ
perfusion.
Levosimendan can be used in AHF during episodes of
low CO and impaired organ perfusion to:
1. Improve hemodynamics (Fig. 2)10 and tissue perfusion;
2. Relieve symptoms of congestion and fatigue12;
3. Augment renal blood ﬂow and glomerular ﬁltration rate
(GFR) through afferent arteriolar dilatation and increase
urine production.
These priorities, and the ability of levosimendan to
meet these needs, are acknowledged in the indication of the
drug for short-term treatment of acutely decompensated
severe chronic heart failure when conventional therapy is
not sufﬁcient, and in cases in which inotropic support
is considered appropriate (Box 2). Dosage in these situa-
tions is guided in part by blood pressure, with bolus
omitted or used only if SBP is ,100 mm Hg. Meta-
analysis of 45 randomized controlled trials in cardiac sur-
gery or cardiology identiﬁes an infusion rate range of 0.05–
0.2 mg$kg21$min21, with some indications that lower rates
(,0.1 mg$kg21$min21) may confer greater survival advan-
tages over higher doses.13
BOX 2.
Expected effects of the use of levosimendan
in AHF
1. Improvement of hemodynamics and tissue perfusion;
2. Relief of symptoms of congestion and fatigue.
Experience from recent large randomized trials
indicates that levosimendan can be considered safe in
high-risk patients who have been exposed to extensive
previous polypharmacy, including beta-blockers.
LEVOSIMENDAN IN AdvHF
Background, Rationale, and Theoretical
Considerations
AdvHF may be identiﬁed in the clinic using the deﬁnition
of the condition proposed by the ESC (Table 1)14,15; it is dif-
ferentiated from end-stage heart failure by the fact that the
cardiac dysfunction and symptoms associated with AdvHF
are still potentially reversible, whereas in end-stage heart fail-
ure, they are not.
Within the broad category of AdvHF, however, some
patients may be severely or very severely ill but relatively
stable, whereas others may be relatively less ill but deterio-
rating rapidly; in those situations, further medical therapy
with i.v. vasoactive drugs may be unnecessary or futile.
Cross-referencing of the criteria for Interagency Registry for
Mechanically Assisted Circulatory Support16,17 grades 4, 5,
or 6 with the ESC deﬁnition may be used, as proposed by
Nieminen et al,18,19 to identify the subset of patients with
AdvHF most likely to beneﬁt from repeated or intermittent
cycles of inodilator therapy.
Patients with AdvHF are on a trajectory which leads
eventually either to a deﬁnitive intervention through heart
transplantation or the installation of a left ventricular assist
device, or to a palliative care pathway. In both cases, the goals of
therapy include hemodynamic stabilization and preservation of
functional capacity, mitigation of symptoms, and preservation of
health-related quality of life. Another key goal, particularly in
the palliative scenario, is prevention of heart failure–related
hospitalization, both as an end in itself and to try to avert the
markedly worsened mortality associated with hospitalization,
which persists for several months after an admission.15,17,19–21
FIGURE 2. In patients with New York Heart Association class
II–IV heart failure of ischemic origin, dosing of levosimendan as
a 10-min bolus of 6–24 mg/kg followed by an infusion of 0.05–
0.2 mg$kg21$min21 was well tolerated and produced favor-
able hemodynamic effects, including enhanced CO and stroke
volume and reduction in PCWP, derived from Nieminen
et al.10 PBO, placebo; DOB, dobutamine.
TABLE 1. European Society of Cardiology Definition of AdvHF
Severe symptoms of heart failure (NYHA class III or IV)
Episodes of ﬂuid retention and/or peripheral hypoperfusion
Objective evidence of severe cardiac dysfunction
Severe impairment of functional capacity
History of $1 heart failure hospitalization in the past 6 mo
Presence of all the above features despite attempts to optimize therapy
NYHA, New York Heart Association.
Derived from Metra et al.14
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Some commentators have recently suggested that
neither New York Heart Association (NYHA) classes IIIb–
IV nor INTERMACS levels 4, 5, and 6 are able to correctly
identify all high-risk patients nor give a real overview of
global health state and the degree of disease of the patients.
Heart failure is indeed a complex condition deﬁned by Neu-
bauer19 as an “engine out of fuel.” To better identify patients
with AdvHF, all the relationships existing between heart,
lung, and peripheral organs should be considered and a unique
picture representing the clinical global status of the patient
that in turn could help to determine treatment.20
All in all, in our opinion, levosimendan seems well suited
as treatment of AdvHF when given as repeated or intermittent
cycles of therapy by virtue of its favorable impact on
hemodynamics, its pharmacokinetics, and its persistence of
effect (for up toz10 days) through its long-acting active metab-
olite OR-1896. Other relevant qualities include the following:
1. No increase in intracellular calcium concentration or myo-
cardial oxygen demand;
2. No attenuation by the concomitant use of beta-
blockers21,22;
3. Renal protection (through increase in peripheral organ
perfusion)22,23;
4. Reduction of natriuretic peptides (considered as bio-
markers of a favorable clinical response).
Meta-analyses in cardiological and noncardiological
settings have produced encouraging signals; it certainly seems
that use of levosimendan in repeated or intermittent cycles is
not associated with the distinct increase in mortality reported
from use of conventional adrenergic inotropes,24–26 but is
associated with a reduction of rehospitalization26 (Box 3).
BOX 3.
Repetitive Use of Levosimendan in AdvHF
Observations in the Levo-Rep, LION-Heart, and
LAICA randomized clinical trials are indicative of clinical
beneﬁts from repetitive-use levosimendan in AdvHF
including reduction in NT-pro-BNP levels and trends
toward reductions in heart failure readmissions and heart
failure–related mortality. Registry data also indicate
a reduction in heart failure–related hospitalizations.
Use of levosimendan in repeated or intermittent
cycles seems not to be associated with the increase in
mortality associated with the use of conventional inotropes.
Clinical Trial Findings
Three recently concluded, randomized, placebo-
controlled, double-blind clinical trials have examined the
application of repeated cycles of levosimendan therapy in this
setting.
Levo-Rep (NCT01065194),6 LION-Heart
(NCT01536132),27 and LAICA (NCT00988806)28 built on
observations from earlier open-label studies that suggested
beneﬁts from levosimendan in this setting, including im-
provements in symptoms, hemodynamics and left ventricular
ejection fraction, modulation of neurohormonal and immune
activation, and, possibly, improvements in survival.29–32
As illustrated by their principal inclusion criteria
(Table 2), these studies included very similar patient popu-
lations. The study protocols for LEVO-Rep and LION-Heart
were also very similar. The protocol for LEVO-Rep speciﬁed
4 cycles of levosimendan therapy (6-hour administration at
0.2 mg$kg21$min21 every 2 weeks); for LION-Heart, the
protocol was extended to include 2 additional cycles of lev-
osimendan therapy in response to intimation from LEVO-
Rep that a larger cumulative dose of levosimendan might
be needed to fully explore the potential of this intervention.
The study dose per cycle was identical in LEVO-Rep and
LION-Heart (0.2 mg$kg21$min21 i.v. levosimendan for
6 hours at 2-week intervals); in LAICA, a lower dose but
a longer duration of treatment was examined (0.1mg$kg21$min
i.v. levosimendan for 24 hours at 30-day intervals for up to
12 months; median 6 months).
LEVO-Rep did not reach its primary endpoint of
functional capacity and clinical status, although it might be
argued (in retrospect) that this was a highly ambitious
outcome. On its secondary endpoints, however, LEVO-Rep
documented a signiﬁcant reduction in N-terminal pro-BNP
(NT-pro-BNP) levels at 8 weeks (P = 0.006) and an improve-
ment in event-free survival (hazard ratio 0.39, 95% conﬁ-
dence interval 0.15–0.98, P = 0.037 by Fisher’s exact test).
Those ﬁndings were recapitulated in LION-Heart, which
described a signiﬁcant beneﬁt from levosimendan on its pri-
mary endpoint of NT-pro-BNP levels (P , 0.001) and the
secondary endpoints of heart failure hospitalization (P =
0.002) and all-cause death or heart failure hospitalization
(P = 0.022). LION-Heart also recorded a signiﬁcant reduction
in the proportion of patients registering a clinically signiﬁcant
TABLE 2. Comparison of Patient Populations in the LEVO-Rep,
LION-Heart, and LAICA Trials
Levo-Rep (n =
120) LION-Heart (n = 69) LAICA (n = 97)
NYHA class III or
IV for .3 mo
NYHA class III/IV for
.4 wk
NYHA class III/IV
LVEF ,35% LVEF ,35% One of the following:
Six-minute walk
distance ,350 m
Episode of pulmonary or
systemic congestion
requiring i.v. vasoactives
within 12 mo
LVEF ,30%
Diastolic dysfunction
$ grade III
PCWP $16 mm Hg
and/or CVP
$12 mm Hg
NT-pro-BNP .3000
ng/mL
More than 1
hospitalization for
HF within 6 mo
See text for further discussion.
Derived from www.ClinicalTrials.gov: NCT01065194 (Levo-Rep),6 NCT01536132
(LION-Heart),27 and NCT00988806 (LAICA).28
NYHA, New York Heart Association; LVEF, left ventricular ejection fraction.
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decline in heart failure–related quality of life at 6 months
(20% vs. 64%; P = 0.022). LAICA was inconclusive
regarding its primary endpoint of heart failure hospitalization
but did reveal an improvement in survival.
In all 3 studies, the safety and tolerability proﬁle of
levosimendan compared favorably with that of placebo, and it
can be argued that experience in all these studies demon-
strated that repetitive application of levosimendan is feasible
and safe, even in an outpatient setting.
Only 1 study (LION-Heart) delivered a positive out-
come on its primary endpoint, but all these studies demon-
strated that repeat-cycle levosimendan reduces NT-pro-BNP
levels, and there were repeated and clear demonstrations of
trends toward reductions in heart failure readmissions and
mortality that are consistent with, and corroborate, the
ﬁndings of meta-analyses.2,24,25
These studies are thus encouraging and strongly
suggestive of clinical beneﬁts from repetitive-use levosimen-
dan in AdvHF, but additional larger studies, perhaps in sicker
patients, are needed to further elucidate the potential of
levosimendan in this setting.
Clinical Experience and Insights
The hemodynamic effects of levosimendan are well
characterized and include enhanced CO and stroke volume
and reduction in PCWP.11 There are accompanying signs of
improved systolic and diastolic ventricular function
(eg, Branzi et al33).
Hemodynamic effects are central to the use of levosi-
mendan in AdvHF, so much so that the absence of
hemodynamic improvement as estimated noninvasively by
impedance cardiography predicts 1-year mortality with better
sensitivity and speciﬁcity than the combination of echocar-
diographic and BNP criteria.34 [Independent predictors of
mortality include a ,10% increase in the cardiac index or
reductions in total peripheral resistance and thoracic ﬂuid
content, a persistent restrictive ﬁlling pattern (E/E0 ratio
.15) and a decline in BNP levels of ,30% from baseline.]
Positive effects on ventricular function and neurohormonal
proﬁle also differentiate levosimendan from agents such as
furosemide and may contribute to reduced mortality35 and
hospitalization rate36 in patients with AdvHF.
New insights into the effects of intermittent levosimen-
dan in AdvHF are provided by the RELEVANT-HF regis-
try,37 which has compiled data from 185 patients treated at
6 centers in Lombardy, Italy. These patients received repeated
levosimendan infusions (0.05–0.2 mg$kg21$min21 without
bolus for 24–48 hours at 2–8-week intervals for a minimum
of 6 months). Most patients (63%) were treated for relief of
symptoms; others were treated as a bridge to transplantation/
implantation of a left ventricular assist device (29%) or deci-
sion/candidacy (8%).
The primary outcome measure of RELEVANT-HF
is the overall duration of hospitalization for heart
failure, expressed as the proportion of days spent in hospital
during the ﬁrst 6 months of repeated levosimendan infusion
compared with the 6 months before starting treatment.
According to that criterion, the use of repeated cycles of
parenteral levosimendan was advantageous, reducing the days
spent in hospital from 9% to 3%. The ability to deliver
a similar scale of beneﬁt from an orally administered regimen
would represent a signiﬁcant advance in the outpatient
management of many patients with AdvHF.
The early and sustained reductions in pulmonary
vascular resistance achievable with levosimendan suggest
that repeat use of this agent may also be beneﬁcial in the
management of pulmonary arterial hypertension (Fig. 3).38
Published data in this area are limited but encouraging,38,39
and further investigations appear warranted.
EFFECTS OF LEVOSIMENDAN AND OTHER
INODILATORS ON RENAL FUNCTION IN ACUTE
AND AdvHF
The relation between worsening renal function and
deterioration of prognosis in AHF or heart failure decompen-
sation is well established and underlies the strong focus on
preservation of renal function in clinical protocols for heart
failure management. An important aspect of this situation is,
however, often underappreciated: a transient deterioration of
estimated GFR, or its surrogate increase in serum creatinine,
is not a marker for worse prognosis provided that relief of
congestion is achieved. The beneﬁcial effects of drugs
targeting the renin–angiotensin–aldosterone system, despite
a sometimes marked elevation of serum creatinine, attest to
that proposition. By contrast, deterioration of eGFR with
persistence of congestion indicates a worse prognosis and an
increased mortality. Hence, decongestion is a major target in
AHF.
Although it certainly is overly simplistic to proﬁle
hemodynamics as the sole cause of end-organ damage,
nevertheless, a number of observations highlight the
importance of hemodynamic factors in the origins of renal
dysfunction in heart failure. In this context, an increase in
CO and a reduction in central venous pressure (CVP) are
FIGURE 3. Levosimendan induced sustained reductions in
pulmonary vascular resistance (PVR) in patients with pulmo-
nary arterial hypertension, derived from Kleber et al.38
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important therapeutic targets. Increasing CO and maintain-
ing an adequate renal perfusion pressure are a quite
apparent goal. Regarding CVP, it must be kept in mind
that the kidneys are encapsulated organs. Therefore, any
increase in pressure within these organs, ie, by edema or
backward failure caused by elevated CVP, may reduce the
GFR. Increasing CO and reducing CVP by decongestion
and ﬂuid removal thus may preserve or restore renal
function.
Data from the DOSE study show that the decongestion
may require high-dose diuretic strategies and that with
successful decongestion improvements in indices of renal
function can occur. Effects on “hard” clinical outcomes are,
however, less certain.40
CO may be augmented by reducing systemic vascular
resistance. In situations in which angiotensin-converting
enzyme inhibitors and angiotensin receptor blockers are not
tolerated (owing to the aforementioned increase in serum
creatinine), good effects may be achieved with a hydralazine–
isosorbide dinitrate combination. By contrast, the use of low-
dose dopamine (so-called “renal” dopamine) is not supported
by the results of the DAD-HF trials41,42 or the ROSE study.43
Similar considerations apply to the use of beta-adrenergic
agents. As noted earlier in this commentary application of
catecholamines increased mortality in the Alarm-HF registry
(Fig. 1).11
Levosimendan is one of the few inodilators to have
been formally studied for its effects on renal function
in heart failure.44 The balance of the evidence indicates
that it has a favorable and sustained effect, although per-
haps not a large one, and that this gain is mediated primar-
ily through hemodynamic actions on both CO and CVP
(Box 4).
BOX 4.
Renal Effects of Levosimendan
The current balance of evidence indicates that
levosimendan has a favorable and sustained effect on renal
function in AHF, mediated primarily through CO and
CVP.
Direct observation of human renal arteries
after administration of levosimendan has demonstrated
renal arterial vasodilatation and augmented renal blood
ﬂow.
In the LIDO study, the sustained improvement in CO
observed after levosimendan therapy was associated with
a moderate but signiﬁcant reduction in serum creatinine
compared with dobutamine.22 A similar effect, also versus
dobutamine, was reported by Yilmaz et al,23 and a sustained
reduction in serum creatinine was demonstrated by Zemljic
and colleagues in patients with heart failure on the waiting list
for transplantation22 and in data from the PORTLAND reg-
istry.45 No comparable effect was recorded in the large
REVIVE I & II trials, although that may be a reﬂection of
the fact that, in those studies, renal data were recorded only as
adverse event ﬁndings.46
Direct observation of human renal arteries after admin-
istration of levosimendan has demonstrated that increase in
GFR and promotion of diuresis is accompanied by renal
arterial vasodilatation and augmented renal blood ﬂow.47
Favorable effects on a range of cardiac and vascular echocar-
diographic indices, biomarker status (including cystatin C),
and New York Heart Association heart failure grade and
duration of hospitalization have been recorded in an observa-
tional study in 96 patients.48
These observations are compatible with a hemodynamic
model of the effect of levosimendan in which enhancement of
CO promotes improved GFR and diuresis, which leads to
decongestion and a lower CVP. That in turn, by virtue of
a prereducing and afterload-reducing effect, promotes further
improvement in both cardiac and renal function. An important
aspect of reduced CVP in this context is its favorable impact
on right ventricular function. In addition to these clinical
ﬁndings, observations in a porcine ischemia–reperfusion
model of renal failure suggest that, beyond its hemody-
namic effects, levosimendan may have additional renal pro-
tective qualities arising from antioxidant, antiapoptotic, and
cytoprotective actions exercised through the opening of
mitochondrial KATP channels and the generation of intrarenal
nitrous oxide.49
Levosimendan emerges from these data as a useful
addition to the clinical resources available to manage
cardiorenal syndrome due to AHF. The published evidence
underlines that levosimendan in this setting compares favor-
able agents such as the vasopressin antagonists (eg, tolvaptan)
and adenosine A1 receptor antagonists (eg, rolophylline).
New investigational drugs such as istaroxime and ryanodine
receptor stabilizers are interesting but of unproven value.
Until studies show the efﬁcacy of these new drugs, we
suggest a focus on individualized therapy using established
drugs after careful consideration of the presenting
pathophysiology.
CONCLUSIONS
Levosimendan occupies a distinctive niche in the
management of AHF and AdvHF, producing a signiﬁcant
relief of heart failure symptoms and exerting a variety of well-
characterized beneﬁcial effects on hemodynamic, functional,
and neurohormonal parameters. Intermittent or repeated
courses of levosimendan have been associated with reduced
need for heart failure–related hospitalizations and an
improved heart-related quality of life. In a number of
meta-analyses, a survival beneﬁt from levosimendan com-
pared with conventional inotropes has been reported.2 At
present, corroboration of that ﬁnding in large controlled trials
remains elusive.
We must highlight, in fact, that although some trials in
the regulatory clinical program (eg, the LIDO trial21) showed
a superiority of levosimendan versus dobutamine, others did
not (eg, the SURVIVE trial7). In the literature, there are
numerous nonregulatory studies showing a superiority of lev-
osimendan,13 but these are usually smaller and often mono-
centric. The question, again, is which kind of evidence is
supported by the large randomized control trials? In the latest
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2 decades, many drugs have failed as treatment of AHF as
a result of study protocols in which the statistical power
required to achieve poorly selected (and overambitious)
primary endpoints created the need of large number of
patients at a large number of centers.50 This need to acquire
data from multiple sources introduced variations in pharma-
cologic and nonpharmacologic measures that had potential
to impair the power of statistical insights. As an example
pertaining to levosimendan, in the SURVIVE study, some
centers applied the study drugs (levosimendan or dobut-
amine) 1–2 days after randomizations, whereas others waited
up to 25 days.51 We are therefore not in full agreement that
large studies per se produce a deﬁnitive answer in ﬁelds
such as AHF or AdvHF, where signs, symptoms, etiologies,
comorbidities, comedications, and center-speciﬁc pharma-
cologic and nonpharmacologic treatment practices are so
heterogeneous.
In our opinion, therefore, the hemodynamic beneﬁts
and distinguished safety proﬁle in at-risk and clinically
unstable patients differentiate levosimendan from conven-
tional inotropes and suggest that its use should be considered
more frequently as an alternative to conventional drugs.
Finally, it must be registered that in many studies,
including relatively large regulatory clinical trials, levosi-
mendan was administered in addition to standard of care
(which means other vasoactive drugs—according to the study
centers). It would indeed be intriguing to perform a post hoc
analysis of those abundant data to verify if combinations of
levosimendan with dobutamine or norepinephrine are beneﬁ-
cial. Until now, only few exploratory studies (eg, Nanas
et al31) showing a beneﬁt of the combination (levosimendan
and dobutamine) have been performed.
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